Company: CGC
Filing Date: 2025-05-30
Form Type: POS AM
Source: 0001104659-25-054925
Chunk: 49

Company: Canopy Growth Corp
Filing Date: 2025-05-30
Form: POS AM
Chunk 49
---
. Patent and Trademark Office, the U.S. Department of Agriculture (the “USDA”) and any state equivalent regulatory agencies over cannabis and hemp (including CBD) products;

•

expectations regarding the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill;

•

our ability to refinance debt as and when required on terms favorable to us and comply with covenants contained in our debt facilities and debt instruments;

•

the impacts of the Company’s strategy to accelerate entry into the U.S. cannabis market through the creation of Canopy USA;

•

expectations for Canopy USA to capitalize on the opportunity for growth in the United States cannabis sector and the anticipated benefits of such strategy;

•

the timing and occurrence of the final tranche closing in connection with the acquisition of Jetty pursuant to the exercise by Canopy USA of options to acquire Jetty;

•

the issuance of additional Common Shares to satisfy any deferred and/or option exercise payments to the shareholders of Mountain High Products, LLC, Wana Wellness, LLC, The Cima Group, LLC and Jetty and the issuance of additional non-voting and non-participating shares in the capital of Canopy USA issuable to us from Canopy USA in consideration thereof;

•

the acquisition of additional Class A shares of Canopy USA in connection with the investment (the “Trust Transaction”) in Canopy USA by the Huneeus 2017 Irrevocable Trust (the “Trust”), including any warrants of Canopy USA issued to the Trust in accordance with the share purchase agreement entered into by the Trust and Canopy USA in connection with the Trust Transaction;

•

expectations regarding the potential success of, and the costs and benefits associated with, our acquisitions, equity investments and dispositions;

<div align='center'>S-8</div>

TABLE OF CONTENTS

•

the grant, renewal and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof;

•

our international activities, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact;

•

our ability to successfully create and launch brands and further create, launch and scale products in jurisdictions where such products are legal and that we currently operate in;

•

the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids;

•

our ability to continue as a going concern;

•

our ability to maintain effective internal control over financial reporting;

•

our expected use of the net proceeds of this offering and the